[1]
|
Lutty, G.A. (2013) Effects of Diabetes on the Eye. Investigative Ophthalmology and Visual Sciences, 54, 81-87. http://dx.doi.org/10.1167/iovs.13-12979
|
[2]
|
Heydari, I., Radi, V., Razmjou, S. and Amiri, A. (2010) Chronic Complications of Diabetes Mellitus in Newly Diagnosed Patients. International Journal of Diabetes Mellitus, 2, 61-63. http://dx.doi.org/10.1016/j.ijdm.2009.08.001
|
[3]
|
Nicholson, B.P. and Schachat, A.P. (2010) A Review of Clinical Trials of Anti-VEGF Agents for Diabetic Retinopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology, 248, 915-930. http://dx.doi.org/10.1007/s00417-010-1315-z
|
[4]
|
Caldwell, R.B., Bartoli, M., Behzadian, M.A., El-Remessey, A.E.B., Al-Shabrawey, M., Platt, D.H. and Caldwell, R.W. (2003) Vascular Endothelial Growth Factor and Diabetic Retinopathy: Pathophysiologic Mechanisms and Treatment Perspectives. Diabetes/Metabolism Research and Reviews, 19, 442-455. http://dx.doi.org/10.1002/dmrr.415
|
[5]
|
Lang, G.E. (2012) Diabetic Macular Edema. Ophthalmologica, 227, 21. http://dx.doi.org/10.1159/000337156
|
[6]
|
Michels, S., Rosenfeld, P.J., Puliafito, C.A., Marcus, E.N. and Venkatraman, A.S. (2005) Systemic Bevacizumab (Avastin) Therapy for Neovascular Age Related Macular Degeneration: Twelve-Week Results of an Uncontrolled Open-Label Clinical Study. Ophthalmology, 112, 1035-1047. http://dx.doi.org/10.1016/j.ophtha.2005.02.007
|
[7]
|
Aiello, L.P., Beck, R.W., Bressler, N.M., Browning, D.J., Chalam, K.V., Davis, M., Ferris, F.L., et al. (2011) Rationale for the Diabetic Retinopathy Clinical Research Network Treatment Protocol for Center-Involved Diabetic Macular Edema. Ophthalmology, 118, 5-14. http://dx.doi.org/10.1016/j.ophtha.2011.09.058
|
[8]
|
Campochiaro, P.A., Heier, J.S., Feiner, L., Gray, S., Saroj, N., Rundle, A.C., Murahasi, W.Y., et al. (2010) Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: Six-Month Primary End Point Results of a Phase III Study. Ophthalmology, 117, 1102-1112. http://dx.doi.org/10.1016/j.ophtha.2010.02.021
|
[9]
|
di Lauro, R., De Ruggiero, P., di Lauro, R., di Lauro, M.T. and Romano, M.R. (2010) Intravitrealbevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology, 248, 785-791. http://dx.doi.org/10.1007/s00417-010-1303-3
|
[10]
|
Elman, M.J., Aiello, L.P., Beck, R.W., Bressler, N.M., Bressler, S.B., Edwards, A.R., Ferris, F.L., et al.(2010) Randomized Trial Evaluating Ranibizumab plus Prompt or Deferred Laser or Triamcinolone plus Prompt Laser for Diabetic Macular Edema. Ophthalmology, 117, 1064-1077. http://dx.doi.org/10.1016/j.ophtha.2010.02.031
|
[11]
|
Elman, M.J., Qin, H., Aiello, L.P., Beck, R.W., Bressler, N.M., Ferris, F.L., Glassman, A.R., et al. (2012) Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment. Ophthalmology, 119, 2312-2318. http://dx.doi.org/10.1016/j.ophtha.2012.08.022
|
[12]
|
Googe, J., Brucker, A.J., Bressler, N.M., Qin, H., Aiello, L.P., Antoszyk, A., Beck, R.W., et al. (2011) Randomized Trial Evaluating Short-Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema after Focal/Grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal Photocoagulation. Retina, 31, 1009-1027. http://dx.doi.org/10.1097/IAE.0b013e318217d739
|
[13]
|
Kook, D., Wolf, A., Kreutzer, T., Neubauer, A., Strauss, R., Ulbig, M., Kampik, A., et al. (2008) Long-Term Effect of Intravitreal Bevacizumab (Avastin) in Patients with Chronic Diffuse Diabetic Macular Edema. Retina, 28, 1053-1060. http://dx.doi.org/10.1097/IAE.0b013e318176de48
|
[14]
|
Kook, P.E., Maier, M., Schuster, T., Feucht, N. and Lohmann, C.P. (2011) Nine-Month Results of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Oedema: A Retrospective Analysis. Acta Ophthalmologica, 89, 769-773. http://dx.doi.org/10.1111/j.1755-3768.2009.01823.x
|
[15]
|
Massin, P., Bandello, F., Garweg, J., Hansen, L., Harding, S.P., Larsen, M., Mitchell, P., et al. (2010) Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study). A 12-Month, Randomized, Controlled, Double-Masked, Multicenter Phase II Study. Diabetes Care, 33, 2399-2405. http://dx.doi.org/10.2337/dc10-0493
|
[16]
|
Mehta, S., Blinder, K.J., Shah, G.K., Kymes, S.M., Schlief, S.L. and Grand, M.G. (2009) Intravitreal Bevacizumab for the Treatment of Refractory Diabetic Macular Edema. Ophthalmic Surgery Lasers and Imaging, 41, 323-329.
|
[17]
|
Michaelides, M., Fraser-Bell, S., Hamilton, R., Kaines, A., Egan, C., Bunce, C., Peto, T., et al. (2010) Macular Perfusion Determined by Fundus Fluorescein Angiography at the 4-Month Time Point in a Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (Bolt Study): Report 1. Retina, 30, 781-786. http://dx.doi.org/10.1097/IAE.0b013e3181d2f145
|
[18]
|
Michaelides, M., Kaines, A., Hamilton, R.D., Fraser-Bell, S., Rajendram, R., Quhill, F., Boos, C.J., et al. (2010) A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study): 12-Month Data: Report 2. Ophthalmology, 117, 1078-1086.e2. http://dx.doi.org/10.1016/j.ophtha.2010.03.045
|
[19]
|
Nguyen, Q.D., Shah, S.M., Heier, J.S., Do, D.V., Lim, J., Boyer, D., Abraham, P., et al. (2009) Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology, 116, 2175-2181. http://dx.doi.org/10.1016/j.ophtha.2009.04.023
|
[20]
|
Nguyen, Q.D., Shah, S.M., Khwaja, A.A., Channa, R., Hatef, E., Do, D.V., Boyer, D., et al. (2010) Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology, 117, 2146-2151. http://dx.doi.org/10.1016/j.ophtha.2010.08.016
|
[21]
|
Oshima, Y., Shima, C., Wakabayashi, T., Kusaka, S., Shiraga, F., Ohji, M. and Tano, Y. (2009) Microincision Vitrectomy Surgery and Intravitreal Bevacizumab as a Surgical Adjunct to Treat Diabetic Traction Retinal Detachment. Ophthalmology, 116, 927-938. http://dx.doi.org/10.1016/j.ophtha.2008.11.005
|
[22]
|
Robaszkiewicz, J., Chmielewska, K., Figurska, M., Wierzbowska, J. and Stankiewicz, A. (2012) Triple Therapy: Phaco-Vitrectomy with ILM Peeling, Retinal Endophotocoagulation, and Intraoperative Use of Bevacizumab for Diffuse Diabetic Macular Edema. Medical Science Monitor, 18, 241-251. http://dx.doi.org/10.12659/MSM.882624
|
[23]
|
Scott, I. and Flynn Jr., H.W. (2007) Reducing the Risk of Endophthalmitis Following Intravitreal Injections. Retina, 27, 10-12. http://dx.doi.org/10.1097/IAE.0b013e3180307271
|
[24]
|
Takamura, Y., Kubo, E. and Akagi, Y. (2009) Analysis of the Effect of Intravitreal Bevacizumab Injection on Diabetic Macular Edema after Cataract Surgery. Ophthalmology, 116, 1151-1157. http://dx.doi.org/10.1016/j.ophtha.2009.01.014
|
[25]
|
Ulbig, M.W., Kampik, A. and Hamilton, A.M. (1993) Diabetic Retinopathy. Epidemiology, Risk Factors and Staging. Ophthalmology, 90, 197-209.
|
[26]
|
He, H., Venema, V.J., Gu, X., Venema, R.C., Marrero, M.B. and Caldwell, R.B. (1999) Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through flk-1/KDR Activation of c-Src. The Journal of Biological Chemistry, 274, 25130-25135. http://dx.doi.org/10.1074/jbc.274.35.25130
|
[27]
|
Foy, K.C., Miller, M.J., Moldovan, N., Carson III, W.E. and Kaumaya, P.T. (2012) Combined Vaccination with HER-2 Peptide Followed by Therapy with VEGF Peptide Mimics Exerts Effective Anti-Tumor and Anti-Angiogenic Effects in Vitro and in Vivo. Oncoimmunology, 1, 1048-1060. http://dx.doi.org/10.4161/onci.20708
|
[28]
|
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M.P., Shi, E., Pyles, E.A., Yancopoulos, G.D., Stahl, N. and Wiegand, S.J. (2012) Binding and Neutralization of Vascular Endothelial Growth Factor (VEGF) and Related Ligands by VEGF Trap, Ranibizumab and Bevacizumab. Angiogenesis, 15, 171-185. http://dx.doi.org/10.1007/s10456-011-9249-6
|
[29]
|
Stewart, M.W. (2012) Anti-Vascular Endothelial Growth Factor Drug Treatment of Diabetic Macular Edema: The Evolution Continues. Current Diabetes Reviews, 8, 237-246. http://dx.doi.org/10.2174/157339912800840488
|
[30]
|
Bhagat, N., Grigorian, R.A., Tutela, A. and Zarbin, M.A. (2009) Dibetic Macular Edema: Pathogenesis and Treatment. Survey of Ophthalmology, 54, 1-32. http://dx.doi.org/10.1016/j.survophthal.2008.10.001
|